Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 08/26/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–08/25/2026 Record Record Date Vuga Group Change Status Recency Days Public Significance Score Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer 06/27/2018 INTERVENTIONAL unchanged 2,982.85 0 Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job 06/28/2018 INTERVENTIONAL unchanged 2,981.85 0 Chronic Effect of Fasting 06/29/2018 INTERVENTIONAL unchanged 2,980.85 0 Breast Aesthetics by Three Dimensional Measures 07/06/2018 OBSERVATIONAL unchanged 2,973.85 0 Study of the Safety and Effectiveness of Motiva Implants® 07/09/2018 INTERVENTIONAL unchanged 2,970.85 0 Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod 07/10/2018 INTERVENTIONAL unchanged 2,969.85 0 Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer 07/11/2018 INTERVENTIONAL unchanged 2,968.85 0 The Effect of Membrane Sweeping on the Delivery Time and the Need of Induction in Term Pregnancy 07/19/2018 INTERVENTIONAL unchanged 2,960.85 0 Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer 07/19/2018 INTERVENTIONAL unchanged 2,960.85 0 Baby's First Years 07/20/2018 INTERVENTIONAL unchanged 2,959.85 0 Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer 07/23/2018 INTERVENTIONAL unchanged 2,956.85 0 Mineral Status in Pregnant Women 07/26/2018 OBSERVATIONAL unchanged 2,953.85 0 A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer 07/27/2018 INTERVENTIONAL unchanged 2,952.85 0 Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF 07/27/2018 INTERVENTIONAL unchanged 2,952.85 0 Non-contrast DWI for Supplemental Screening 07/31/2018 OBSERVATIONAL unchanged 2,948.85 0 A Culturally-tailored Personalized Nutrition Intervention in South Asian Women at Risk of Gestational Diabetes 07/31/2018 INTERVENTIONAL unchanged 2,948.85 0 SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer 08/03/2018 INTERVENTIONAL unchanged 2,945.85 0 Pessary Satisfaction Criteria for Urogenital Prolapse 08/06/2018 OBSERVATIONAL unchanged 2,942.85 0 Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. 08/06/2018 INTERVENTIONAL unchanged 2,942.85 0 Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC 08/06/2018 INTERVENTIONAL unchanged 2,942.85 0 Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer 08/06/2018 INTERVENTIONAL unchanged 2,942.85 0 Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer 08/07/2018 OBSERVATIONAL unchanged 2,941.85 0 Development of Advanced Double Intravenous Vasopressor Automated (ADIVA) System 08/08/2018 INTERVENTIONAL unchanged 2,940.85 0 PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer 08/09/2018 OBSERVATIONAL unchanged 2,939.85 0 Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinical Characterization 08/09/2018 OBSERVATIONAL unchanged 2,939.85 0 Comparative Antiresorptive Efficacy Discontinuation of Denosumab 08/09/2018 INTERVENTIONAL unchanged 2,939.85 0 Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) 08/10/2018 INTERVENTIONAL unchanged 2,938.85 0 CFI-400945 in Patients With Advanced/Metastatic Breast Cancer 08/10/2018 INTERVENTIONAL unchanged 2,938.85 0 Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms 08/10/2018 OBSERVATIONAL unchanged 2,938.85 0 Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection 08/10/2018 OBSERVATIONAL unchanged 2,938.85 0 Maternal Outcomes Following Manual Lysis of the Placenta. 08/13/2018 INTERVENTIONAL unchanged 2,935.85 0 Maternal Grandmothers in the Born in Guangzhou Cohort Study 08/16/2018 OBSERVATIONAL unchanged 2,932.85 0 Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS 08/16/2018 INTERVENTIONAL unchanged 2,932.85 0 MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer 08/16/2018 INTERVENTIONAL unchanged 2,932.85 0 Multidisciplinary Treatment of Chronic Vulvar Pain 08/21/2018 INTERVENTIONAL unchanged 2,927.85 0 Post-operative Emesis and Pain Outcomes After Cesarean Delivery 08/24/2018 OBSERVATIONAL unchanged 2,924.85 0 Improving Sleep Quality During Pregnancy Using an Oral Appliance 08/24/2018 INTERVENTIONAL unchanged 2,924.85 0 Partial Breast Versus no Irradiation for Women With Early Breast Cancer 08/24/2018 INTERVENTIONAL unchanged 2,924.85 0 The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's 08/28/2018 INTERVENTIONAL unchanged 2,920.85 0 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients 08/29/2018 INTERVENTIONAL unchanged 2,919.85 0 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib 08/29/2018 INTERVENTIONAL unchanged 2,919.85 0 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone 09/07/2018 INTERVENTIONAL unchanged 2,910.85 0 Investigating the Structured Use of Ultrasound Scanning for Fetal Growth 09/07/2018 OBSERVATIONAL unchanged 2,910.85 0 Intravenous Estrogen in Kidney Transplant Study 09/10/2018 INTERVENTIONAL unchanged 2,907.85 0 Postpartum Low-Dose Aspirin and Preeclampsia 09/12/2018 INTERVENTIONAL unchanged 2,905.85 0 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma 09/12/2018 INTERVENTIONAL unchanged 2,905.85 0 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients 09/14/2018 INTERVENTIONAL unchanged 2,903.85 0 Laser Vaginal Treatment for SUI 09/14/2018 INTERVENTIONAL unchanged 2,903.85 0 Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy 09/14/2018 INTERVENTIONAL unchanged 2,903.85 0 My Personalized Breast Screening 09/14/2018 INTERVENTIONAL unchanged 2,903.85 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 08/26/2026 · upstream last modified 08/26/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Public Significance Score using the documented compute method. · methodology